These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36142179)

  • 1. Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
    da Costa NF; Daniels R; Fernandes AI; Pinto JF
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
    da Costa NF; Fernandes AI; Pinto JF
    Int J Pharm; 2020 Oct; 588():119716. PubMed ID: 32758593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement.
    da Costa NF; Santos IA; Fernandes AI; Pinto JF
    J Pharm Sci; 2022 Dec; 111(12):3327-3339. PubMed ID: 36007560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.
    da Costa NF; Daniels R; Fernandes AI; Pinto JF
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 35893791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Situ Co-Amorphization of Olanzapine in the Matrix and on the Coat of Pellets.
    da Costa NF; Azevedo RF; Lopes JA; Fernandes AI; Pinto JF
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Simultaneous Differential Scanning Calorimetry-X-ray Diffraction Study of Olanzapine Crystallization from Amorphous Solid Dispersions.
    Askin S; Gonçalves AD; Zhao M; Williams GR; Gaisford S; Craig DQM
    Mol Pharm; 2020 Nov; 17(11):4364-4374. PubMed ID: 33074007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine.
    Pina MF; Zhao M; Pinto JF; Sousa JJ; Craig DQ
    J Pharm Sci; 2014 Apr; 103(4):1214-23. PubMed ID: 24765654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Insight Into the Impact of Polymers on the Hydrate Conversion of Olanzapine Form I in Aqueous Suspensions.
    Paisana MC; Wahl MA; Pinto JF
    J Pharm Sci; 2017 Jul; 106(7):1786-1794. PubMed ID: 28322942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
    Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
    Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microfibrous Solid Dispersions of Poorly Water-Soluble Drugs Produced via Centrifugal Spinning: Unexpected Dissolution Behavior on Recrystallization.
    Marano S; Barker SA; Raimi-Abraham BT; Missaghi S; Rajabi-Siahboomi A; Aliev AE; Craig DQM
    Mol Pharm; 2017 May; 14(5):1666-1680. PubMed ID: 28296409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of amorphization method on telmisartan solubility and the tableting process.
    Lepek P; Sawicki W; Wlodarski K; Wojnarowska Z; Paluch M; Guzik L
    Eur J Pharm Biopharm; 2013 Jan; 83(1):114-21. PubMed ID: 23085331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
    Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
    Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin.
    Shi X; Song S; Ding Z; Fan B; Huang W; Xu T
    J Pharm Sci; 2019 Sep; 108(9):3020-3028. PubMed ID: 31067482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
    Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2017 Oct; 119():150-160. PubMed ID: 28602869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
    Fael H; Demirel AL
    Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
    Ojarinta R; Saarinen J; Strachan CJ; Korhonen O; Laitinen R
    Eur J Pharm Biopharm; 2018 Nov; 132():112-126. PubMed ID: 30248394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.